Mitral Valve

The heart's mitral valve is the site of the most surgical valve repairs and valve replacements. After the resounding success of transcatheter aortic valve replacement (TAVR), which now makes up more than 50% of aortic valve replacements, there is wide expectation transcatheter mitral replacements will follow in the next few year. Currently, the most common transcatheter mitral procedure is transcatheter edge-to-edge (TEER) , using the MitraClip or Pascal clip devices. These devices are also being used for transcatheter tricuspid valve repair (TTVR). Other transcatheter mitral repair systems are in trials for minimally invasive annuloplasty and chordae tendineae repair.

Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data
The new-look mitral valve is built using LifePolymer, a proprietary material that does not include any animal tissue. Both the frame and its leaflets are robotically generated to match each patient’s anatomy.
Late-breaking clinical trials announced for New York Valves 2025
The three-day event is now in its second year. Each day will feature late-breaking clinical trials focused on a different heart valve.
‘A compelling alternative’: Polymer heart valve receives first commercial approval of its kind
A new surgical mitral valve from Foldax will now be commercially available in India. The valve is built using LifePolymer, a proprietary material that does not include animal tissue.
Heart surgeons perform world’s first robotic TAVR explant and aortic valve replacement
The patient, 67, presented with a failing TAVR valve and a leaky mitral valve. She had undergone TAVR four years prior, but premature structural valve degeneration made a full replacement necessary. Surgeons ultimately removed the TAVR valve in addition to replacing her aortic and mitral valves—all with the help of advanced robotics.
FDA approves self-expanding Tendyne TMVR device from Abbott
The self-expanding valve, which gained CE mark approval back in 2020, is available in multiple sizes and can be fully retrieved and repositioned as it is implanted.

TMVR outcomes suffer when patients have heart failure and diabetes—but benefits remain

Overall, the authors emphasized, TMVR helped heart failure patients with and without diabetes.

Next-day discharge after TMVR is on the rise

By 2018, nearly half of all TMVR patients were going home the very next day. Outcomes for these patients have been consistently positive.

TEER shows potential to boost outcomes for cardiogenic shock patients

Cardiogenic shock has been linked to a heightened risk of morbidity and mortality. TEER, it seems, may be able to help provide patients with some relief.

How diabetes impacts TEER outcomes

The new analysis, published in JACC: Heart Failure, focused on patient data from the renowned COAPT trial.

Risk score predicts outcomes for heart failure patients undergoing TEER

The new analysis included data from nearly 700 patients who underwent TEER, formerly known as TMVR, over an eight-year period.

Surgery still more common than TMVR among AMI patients, but the gap is shrinking

The study's authors emphasized how important it is for clinicians to work together to determine the best treatment strategy.

Significant MR after TAVR linked to higher mortality rates—but staged interventions may help

Percutaneous edge-to-edge mitral valve repair was associated with improved outcomes among TAVR patients with persistent mitral regurgitation.

When TEER fails, most patients require mitral valve replacement

The team's findings were presented at the 101st Annual Meeting of the American Association for Thoracic Surgery and published in the Journal of the American College of Cardiology.

Mitral Valve

Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data

Late-breaking clinical trials announced for New York Valves 2025

‘A compelling alternative’: Polymer heart valve receives first commercial approval of its kind

Heart surgeons perform world’s first robotic TAVR explant and aortic valve replacement

FDA approves self-expanding Tendyne TMVR device from Abbott